Abeona (ABEO) Reports $11.4M Q2 Revenue Growth of 31%
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOn August 13, Abeona Therapeutics (NASDAQ: ABEO) reported second-quarter revenue of $11.4 million, up 31% from $8.7 million in the prior quarter. The company has treated 12 patients with its gene therapy ZEVASKYN, expanding its treatment center network to seven sites, including Cincinnati Children's. Despite the revenue growth, net losses widened to $20.2 million, or $0.35 per share. The company's new technology payment from Medicare, effective October 1, 2026, highlights ongoing support for its innovative treatments, making it relevant for investors monitoring biotech advancements.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
